Cell proliferation pathways and extracellular matrix (ECM)-associated gene sets are consistently down-regulated in both ER-negative and ER-positive cells, emphasizing the shared growth-suppressive effects of G9a inhibition and underscoring its significant therapeutic potential across these breast cancer subtypes (Figure 7C). Here, ESR1 is linked to breast carcinoma.